AIDS-associated malignancies; etiology, animal models and treatments (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

AIDS-associated malignancies; etiology, animal models and treatments (Meeting abstract).

Anticancer Res; 12(6A):1784-5 1992. Unique Identifier : AIDSLINE ICDB/93696202
Nigam VN; Madarnas P; Naik R; Turgeon R; Dept. of Anatomy, Faculty of Medicine, Univ. of Sherbrooke,; Sherbrooke, Quebec J1H 5N4, Canada

Abstract: Spread of HIV infection worldwide and increased survival of AIDS patients forebodes emergence of AIDS-associated cancers of epidemic proportions. The cancers comprise Kaposi's sarcoma, non-Hodgkin's B-cell lymphoma and genital-anorectal carcinomas. Etiologic agents remain unknown except that immunosuppressed state is a cofactor. The present paper will review various hypotheses in the evolution of AIDS-related neoplasms. Persistent immune stimulation, cytokine release, dysfunction of specific lymphoid cells controlling proliferation of certain cell types and their subsequent immortalization by endogenous chemicals and viruses will be discussed. Next, an animal model of AIDS-associated malignancies will be presented which will consist of dimethylhydrazine (DMH)-induced angiosarcoma (as an internal KS equivalent) and colon-anal carcinomas and LPBM5 (MAIDS virus) induced immune suppression, lymphadenopathy and B-cell neoplasms. Culture of DMH-induced angiosarcoma will be described. Lastly, the paper will propose immunotherapy with maltose tetrapalmitate (MTP) alone or with low-dose cyclophosphamide at the asymptomatic stage of AIDS because of MTP localization to lymph nodes (a hiding place for virus) and angiotherapy with nonimmunosuppressive steroid and MTP to prevent tumor vol increase.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/IMMUNOLOGY/ METABOLISM/THERAPY Animal Anus Neoplasms/IMMUNOLOGY Cell Division Colonic Neoplasms/IMMUNOLOGY Cyclophosphamide/ADMINISTRATION & DOSAGE Cytokines/METABOLISM Dimethylhydrazines/ADVERSE EFFECTS Glycolipids/ADMINISTRATION & DOSAGE Hemangiosarcoma/CHEMICALLY INDUCED/COMPLICATIONS Immunization Immunotherapy Lymphocytes/METABOLISM Lymphoma, B-Cell/IMMUNOLOGY Murine Acquired Immunodeficiency Syndrome/IMMUNOLOGY Steroids/THERAPEUTIC USE ABSTRACT
931030
M93A0777

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .